Home / Resource Library / Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Final Results f the R2-GDP-GOTEL Trial and Immune Biomarker subanalysis

Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Final Results f the R2-GDP-GOTEL Trial and Immune Biomarker subanalysis

Membership Organisation

Healthcare Professional

Affected by Lymphoma

Researcher or Advocate

Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Final Results f the R2-GDP-GOTEL Trial and Immune Biomarker subanalysis